Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Vaccination Against HPV16 for Anal Intraepithelial Neoplasia in HIV-Positive Men
2012-005466-34Phase 2Active
- Sponsor
- Academic Medical Center
- Start
- May 2013
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of SLP-HPV-01 in anal intraepithelial neoplasia (AIN) and HPV16 infection (HPV16), sponsored by Academic Medical Center. Primary endpoint: Toxicity and safety. Started May 2013; status: active.
02
Drugs
SLP-HPV-01
03
Conditions
anal intraepithelial neoplasia (AIN)HPV16 infection (HPV16)
Beyond the preview
Go deeper on 2012-005466-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005466-34.